Rare Daily Staff

SalioGen Therapeutics said it completed an oversubscribed $115 million series B financing to advance development of its Gene Coding platform, which it describes as a new category of genetic medicine.

GordonMD Global Investments and EPIQ Capital Group led the financing with participation by new investors Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, the RD Fund (the venture arm of Foundation Fighting Blindness), and others. The round also included continued support from PBM Capital, which led the company’s Series A round.

“Grounded by a shared mission to transform the treatment paradigm for patients with inherited diseases, the team and advisory boards we’ve built have unparalleled expertise to usher in the first applications of Gene Coding,” said Ray Tabibiazar, CEO and chairman of SalioGen.

SalioGen’s Gene Coding platform is designed to turn on, turn off or modify the function of any gene in the genome. Gene Coding is applied through SalioGen’s Exact DNA Integration Technology (EDIT), which is based on mammal-derived genome engineering enzymes collectively. With this portfolio of enzymes, the technology can integrate new DNA sequences of any length directly into a defined location in the genome, without the use of viral vectors. The Gene Coding platform is designed to address the limitations of current genetic medicine approaches, including gene editing and viral vector-based gene therapies, and to realize the potential of genetic medicines to reach broader patient populations.

Proceeds from the financing are expected to be used to continue building out the Gene Coding platform, expand the company’s team, establish manufacturing and automation capabilities critical for Gene Coding and accelerate the advancement of its preclinical programs, which are initially focusing on inherited macular disorder and inherited lipid disorders.

Ray Tabibiazar, CEO and chairman of SalioGen

X